Skip to Main Content

Author Details

Annette T Byrne
Royal College of Surgeons in Ireland (RCSI)
1999
67
29
PMIDPaper TitleJournal TitlePublished Year
36903411BF<sub>2</sub>-Azadipyrromethene Fluorophores for Intraoperative Vital Structure Identification.Molecules2023
37237151Comparative analysis of deeply phenotyped GBM cohorts of 'short-term' and 'long-term' survivors.J Neurooncol2023
35631376Refining Glioblastoma Surgery through the Use of Intra-Operative Fluorescence Imaging Agents.Pharmaceuticals (Basel)2022
35434898Implementing subtype-specific pre-clinical models of breast cancer to study pre-treatment aspirin effects.Cancer Med2022
34426441Molecular Subtyping Combined with Biological Pathway Analyses to Study Regorafenib Response in Clinically Relevant Mouse Models of Colorectal Cancer.Clin Cancer Res2021
31622621Therapeutic Targeting of the Colorectal Tumor Stroma.Gastroenterology2020
33256106Targeting the RhoGEF βPIX/COOL-1 in Glioblastoma: Proof of Concept Studies.Cancers (Basel)2020
33066609Implementing Systems Modelling and Molecular Imaging to Predict the Efficacy of BCL-2 Inhibition in Colorectal Cancer Patient-Derived Xenograft Models.Cancers (Basel)2020
32555399Combination of variations in inflammation- and endoplasmic reticulum-associated genes as putative biomarker for bevacizumab response in KRAS wild-type colorectal cancer.Sci Rep2020
30972664RGD-decorated cholesterol stabilized polyplexes for targeted siRNA delivery to glioblastoma cells.Drug Deliv Transl Res2019
31842413Implementing Patient-Derived Xenografts to Assess the Effectiveness of Cyclin-Dependent Kinase Inhibitors in Glioblastoma.Cancers (Basel)2019
31300350Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor A.EBioMedicine2019
31384312Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08-10 trial.Ther Adv Med Oncol2019
31235775Durability of cell line xenograft resection models to interrogate tumor micro-environment targeting agents.Sci Rep2019
30863365When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?Front Endocrinol (Lausanne)2019
30768761Implementing Reverse Phase Protein Array Profiling as a Sensitive Method for the Early Pre-Clinical Detection of Off-Target Toxicities Associated with Sunitinib Malate.Proteomics Clin Appl2019
29792754Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab.J Clin Oncol2018
30046049Anti-angiogenic drug scheduling optimisation with application to colorectal cancer.Sci Rep2018
29879147Interrogation of transcriptomic changes associated with drug-induced hepatic sinusoidal dilatation in colorectal cancer.PLoS One2018
30291241Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy.Nat Commun2018
30262882Author Correction: Anti-angiogenic drug scheduling optimisation with application to colorectal cancer.Sci Rep2018
28611295Assessment of concordance between fresh-frozen and formalin-fixed paraffin embedded tumor DNA methylation using a targeted sequencing approach.Oncotarget2017
28487489Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancer.Oncotarget2017
28104906Interrogating open issues in cancer precision medicine with patient-derived xenografts.Nat Rev Cancer2017
28129334A Novel Positron Emission Tomography (PET) Approach to Monitor Cardiac Metabolic Pathway Remodeling in Response to Sunitinib Malate.PLoS One2017
29092942PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models.Cancer Res2017
28912576Interrogating open issues in cancer medicine with patient-derived xenografts.Nat Rev Cancer2017
26997367Targeting the 19S proteasomal subunit, Rpt4, for the treatment of colon cancer.Eur J Pharmacol2016
26657652Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant.Br J Cancer2016
27756074Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative.Digestion2016
27353429The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy?Expert Opin Ther Targets2016
27515171AKT1 (E17K) mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection.BMC Cancer2016
27155046Modelling tumour cell proliferation from vascular structure using tissue decomposition into avascular elements.J Theor Biol2016
26975402Mechanistic interrogation of combination bevacizumab/dual PI3K/mTOR inhibitor response in glioblastoma implementing novel MR and PET imaging biomarkers.Eur J Nucl Med Mol Imaging2016
24735997Comparison of anthropometric-based equations for estimation of body fat percentage in a normal-weight and overweight female cohort: validation via air-displacement plethysmography.Public Health Nutr2015
27600244Integrating Colon Cancer Microarray Data: Associating Locus-Specific Methylation Groups to Gene Expression-Based Classifications.Microarrays (Basel)2015
25820126The chain length of biologically produced (R)-3-hydroxyalkanoic acid affects biological activity and structure of anti-cancer peptides.J Biotechnol2015
24518591Guanine nucleotide exchange factor Dock7 mediates HGF-induced glioblastoma cell invasion via Rac activation.Br J Cancer2014
25491032Comparison of performance in a four year graduate entry medical programme and a traditional five/six year programme.BMC Med Educ2014
25375271Interrogation of gossypol therapy in glioblastoma implementing cell line and patient-derived tumour models.Br J Cancer2014
25185190Patient-derived xenograft models: an emerging platform for translational cancer research.Cancer Discov2014
24952322Validation of an imageable surgical resection animal model of Glioblastoma (GBM).J Neurosci Methods2014
24876102Neuromedin U: a candidate biomarker and therapeutic target to predict and overcome resistance to HER-tyrosine kinase inhibitors.Cancer Res2014
23343631The anti-cancer activity of a cationic anti-microbial peptide derived from monomers of polyhydroxyalkanoate.Biomaterials2013
23792334Molecular imaging in the development of a novel treatment paradigm for glioblastoma (GBM): an integrated multidisciplinary commentary.Drug Discov Today2013
23490442In vivo bioluminescence imaging validation of a human biopsy-derived orthotopic mouse model of glioblastoma multiforme.Mol Imaging2013
21413012Mechanism of cell death mediated by a BF2-chelated tetraaryl-azadipyrromethene photodynamic therapeutic: dissection of the apoptotic pathway in vitro and in vivo.Int J Cancer2012
20229355Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells.Invest New Drugs2011
21789714Examining the role of Rac1 in tumor angiogenesis and growth: a clinically relevant RNAi-mediated approach.Angiogenesis2011
21844787The hydroxylase inhibitor dimethyloxallyl glycine attenuates endotoxic shock via alternative activation of macrophages and IL-10 production by B1 cells.Shock2011
  • 1 - 50 of 67

Recommended Authors

Cristina Ivan
The University of Texas MD Anderson Cancer Center
Career Start Year 2010
Number of shared co-authors 2
Minhyung Kim
Roswell Park Comprehensive Cancer Center
Career Start Year 2010
Number of shared co-authors 0
Chad V Pecot
University of North Carolina at Chapel Hill
Career Start Year 2009
Number of shared co-authors 1
Bo Gao
Crown Princess Mary Cancer Centre, Westmead Hospital
Career Start Year 2008
Number of shared co-authors 0
Jordi Rodon
The University of Texas MD Anderson Cancer Center
Career Start Year 2006
Number of shared co-authors 3
Ludwig Dubois
Maastricht University
Career Start Year 2004
Number of shared co-authors 1
Trevor D McKee
University Health Network
Career Start Year 2001
Number of shared co-authors 1
Ping Guo
Steadman Philippon Research Institute, Center for Regenerative Sports Medicine
Career Start Year 2001
Number of shared co-authors 0
Christopher D Willey
University of Alabama at Birmingham
Career Start Year 2000
Number of shared co-authors 0
David J Liewehr
Center for Cancer Research
Career Start Year 1999
Number of shared co-authors 0
Martijn P Lolkema
Erasmus MC Cancer Institute
Career Start Year 1999
Number of shared co-authors 8
Francesca M Buffa
University of Oxford
Career Start Year 1998
Number of shared co-authors 2
Nhu-An Pham
Princess Margaret Cancer Centre, University Health Network
Career Start Year 1998
Number of shared co-authors 0
Paul Haluska
Mayo Clinic
Career Start Year 1996
Number of shared co-authors 1
Christopher Ryan Miller
University of Illinois at Urbana-Champaign
Career Start Year 1996
Number of shared co-authors 3
Shi-Yuan Cheng
Northwestern University Feinberg School of Medicine
Career Start Year 1996
Number of shared co-authors 2
John D Gordan
Quantitative Biosciences Institute (QBI), University of California San Francisco
Career Start Year 1996
Number of shared co-authors 1
Stanley K Liu
Odette Cancer Centre, University of Toronto
Career Start Year 1995
Number of shared co-authors 0
Jacqueline F Donoghue
University of Melbourne
Career Start Year 1995
Number of shared co-authors 0
Kevin Camphausen
National Cancer Institute
Career Start Year 1994
Number of shared co-authors 0
Stefan Sleijfer
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Career Start Year 1994
Number of shared co-authors 3
Paul N Span
Radboud University Medical Center
Career Start Year 1993
Number of shared co-authors 4
Craig Gedye
Hunter Medical Research Institute, University of Newcastle
Career Start Year 1993
Number of shared co-authors 0
Anil K Sood
The University of Texas MD Anderson Cancer Center
Career Start Year 1991
Number of shared co-authors 0
Joan Albanell
Hospital del Mar Research Institute
Career Start Year 1990
Number of shared co-authors 1
Emile E Voest
The Netherlands Cancer Institute
Career Start Year 1989
Number of shared co-authors 9
Luc Dirix
GZA Ziekenhuizen Campus Sint-Augustinus, University of Antwerp
Career Start Year 1988
Number of shared co-authors 6
Kenneth R Hess
The University of Texas MD Anderson Cancer Center
Career Start Year 1986
Number of shared co-authors 2
Adrian L Harris
University of Oxford
Career Start Year 1981
Number of shared co-authors 2
Antonio Jimeno
University of Colorado School of Medicine
Career Start Year 1974
Number of shared co-authors 2

Collaborators

William M Gallagher
All-Island Cancer Research Institute, UCD Conway Institute, University College Dublin
Co-authored papers 25
Diether Lambrechts
Co-authored papers 8
Timo Gaiser
Institut fur Pathologie, Universitatsmedizin Mannheim
Co-authored papers 7
Bauke Ylstra
Cancer Center Amsterdam, Vrije Universiteit Amsterdam
Co-authored papers 6
Livio Trusolino
Candiolo Cancer Institute - FPO IRCCS
Co-authored papers 6
Andrea Bertotti
Candiolo Cancer Institute - FPO IRCCS
Co-authored papers 5
Rut Klinger
UCD Conway Institute, University College Dublin
Co-authored papers 5
Darran P O'Connor
UCD Conway Institute, University College Dublin
Co-authored papers 5
Carlos Caldas
Cancer Research UK Cambridge Institute, University of Cambridge
Co-authored papers 4
Enzo Medico
Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO) - IRCCS
Co-authored papers 4
Fr??d??ric Amant
Netherlands Cancer Institute
Co-authored papers 4
Jos Jonkers
Oncode Institute, Netherlands Cancer Institute
Co-authored papers 4
Els Hermans
Netherlands Cancer Institute
Co-authored papers 3
Daniel S Peeper
Netherlands Cancer Institute
Co-authored papers 3
Elisabetta Marangoni
Co-authored papers 3
Emilie Vinolo
CNRS URA 5
Co-authored papers 3
Alejandra Bruna
CRUK Cambridge Institute, University of Cambridge
Co-authored papers 3
Kristel Kemper
Oncode Institute, The Netherlands Cancer Institute
Co-authored papers 3
Oscar M Rueda
University of Cambridge
Co-authored papers 3
Hans Clevers
Princess Maxima Center for Pediatric Oncology
Co-authored papers 2
Keith L Ligon
Co-authored papers 2
Sharon F McGee
The Ottawa Hospital Cancer Centre
Co-authored papers 2
Theodore C Goldstein
Bakar Computational Health Sciences Institute, University of California san francisco
Co-authored papers 1
Jane Cryan
Co-authored papers 1
Amanda L Christie
Dana-Farber Cancer Institute
Co-authored papers 1
Marcel Kool
Hopp Children's Cancer Center (KiTZ)
Co-authored papers 1
Jeremy Mason
European Molecular Biology Laboratory - European Bioinformatics Institute
Co-authored papers 1
Stefan M Pfister
Hopp Children's Cancer Center Heidelberg (KiTZ)
Co-authored papers 1
Mairin Rafferty
Oncomark Ltd.
Co-authored papers 1
Saravut J Weroha
Mayo Clinic
Co-authored papers 1
Release 1.2